ACXP · Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals Inc (ACXP)
What's happening
- ACXP is down 0.43% today, trading at $1.15. — Live quote
- It's trading within 3% of its 52-week low ($1.07). (Finnhub fundamentals)
- Volume today (300) is well below its 3-month average of 114,200. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.53 actual vs. $-0.38 estimated (-37.9%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $6.6M | $10.0M | $6.6M | $12.2M | $7.8M |
| P/E | -0.80 | -1.24 | -0.72 | -1.08 | -0.58 |
| Price/Book | 0.81 | 1.42 | 1.82 | 3.43 | 3.37 |
| ROE | -100.27% | -115.06% | -253.22% | -317.94% | -582.79% |
| ROA | -74.41% | -84.58% | -150.85% | — | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-16; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -83.6%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ACXP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$2.3M | -$1.7M | -$2.0M | -$2.3M | -$2.2M | -$2.8M | -$4.1M | — |
| Net income | -$2.3M | -$1.7M | -$2.0M | -$2.2M | -$2.1M | -$2.8M | -$4.1M | -$4.4M |
| EPS (diluted) | $-0.53 | $-0.62 | $-1.23 | $-1.89 | $-2.15 | $-3.45 | $-5.21 | $-0.28 |
| EPS (basic) | $-0.53 | $-0.62 | $-1.23 | $-1.89 | $-2.15 | $-3.45 | $-5.21 | $-0.28 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $11.0M | $9.5M | $7.7M | $6.1M | — | — | $3.9M | — |
| Total liabilities | $2.8M | $2.5M | $2.4M | $2.5M | $2.6M | $2.5M | $3.2M | $3.3M |
| Stockholders' equity | $8.2M | $7.0M | $5.3M | $3.6M | $3.6M | $2.3M | $615.1K | $2.7M |
| Total current assets | — | — | — | — | $6.2M | $4.8M | $3.9M | $6.0M |
| Total current liabilities | $2.8M | $2.5M | $2.4M | $2.5M | $2.6M | $2.5M | $3.2M | $3.3M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.7K | $3.4K | $2.3K | $1.8K | $1.5K | $22.4K | $852 | $16.8K |
| Retained earnings | -$79.2M | -$77.0M | -$75.3M | -$73.7M | -$71.7M | -$69.5M | -$67.3M | -$64.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.7M | -$1.4M | -$1.2M | -$1.9M | -$1.7M | -$2.1M | -$2.3M | -$2.2M |
| Financing cash flow | $3.1M | $3.1M | $2.8M | $1.7M | $3.1M | $3.0M | $194.5K | $1.6M |
| Share-based compensation | $200.5K | $258.3K | $294.8K | $294.8K | $324.2K | $333.6K | $345.2K | $345.2K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$8.1M | -$14.1M | — | — | — |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| EPS (diluted) | $-5.32 | $-17.45 | $-1.15 | $-1.12 | $-1.49 |
| EPS (basic) | $-5.32 | $-17.45 | $-1.15 | $-1.12 | $-1.49 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K |
| Stockholders' equity | $5.3M | $615.1K | $4.7M | $7.3M | $12.4M |
| Total current liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K |
| Common stock & paid-in capital | $2.3K | $852 | $14.5K | $11.6K | $10.2K |
| Retained earnings | -$75.3M | -$67.3M | -$53.2M | -$38.6M | -$26.5M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Financing cash flow | $10.6M | $6.6M | $8.2M | $3.7M | $14.8M |
| Share-based compensation | $1.2M | $2.6M | $3.2M | $2.9M | $5.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ACXP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-06 to 2025-01-06
Recent transactions
- Most recent: Scodari Joseph C (Director) — Open market purchase of 24,631 shares on 2025-01-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Scodari Joseph C | Director | Open market purchase | 2025-01-06 | 24,631 |
| Sailer Carl | Director | Open market purchase | 2025-01-06 | 24,631 |
| LUCI DAVID P | President and CEO | Open market purchase | 2025-01-06 | 49,261 |
| Donohue James J. | Director | Open market purchase | 2025-01-06 | 9,852 |
| DELUCCIA ROBERT J | Director | Open market purchase | 2025-01-06 | 49,261 |
| DEAN JACK H | Director | Open market purchase | 2025-01-06 | 9,852 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-01-06 | Scodari Joseph C | Director | Open market purchase | 24,631 | $1.01 |
| 2025-01-06 | Sailer Carl | Director | Open market purchase | 24,631 | $1.01 |
| 2025-01-06 | LUCI DAVID P | President and CEO | Open market purchase | 49,261 | $1.01 |
| 2025-01-06 | Donohue James J. | Director | Open market purchase | 9,852 | $1.01 |
| 2025-01-06 | DELUCCIA ROBERT J | Director | Open market purchase | 49,261 | $1.01 |
| 2025-01-06 | DEAN JACK H | Director | Open market purchase | 9,852 | $1.01 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 05:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-16 | 8-K | 2026-10-16 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-05-11 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-22 | 4 | 2026-04-20 | View on SEC.gov → |
| 2026-04-16 | 8-K | 2026-04-15 | View on SEC.gov → |
Recent news
Headlines about ACXP (Acurx Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
Yahoo · 2026-10-21 -
ACXP 8-K & SEC Filings
Yahoo Finance · 2026-10-16 -
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
Yahoo Finance · 2026-10-05 -
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
Yahoo Finance · 2026-09-29 -
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
Yahoo Finance · 2026-09-19 -
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
Yahoo Finance · 2026-09-14 -
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
Yahoo Finance · 2026-08-21 -
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstat
Seeking Alpha · 2026-08-14
No headlines in this category right now — try “All”.